GEN 004

Drug Profile

GEN 004

Alternative Names: GEN-004; Pneumococcal vaccine - Genocea/PATH/Childrens Hospital Boston; Prophylactic Streptococcus pneumoniae vaccine - Genocea Biosciences; Streptococcus pneumoniae prophylactic vaccine - Genocea/PATH/Childrens Hospital

Latest Information Update: 03 Nov 2016

Price : $50

At a glance

  • Originator Genocea Biosciences
  • Class Antibacterials; Pneumococcal vaccines
  • Mechanism of Action Immunostimulants; Th17 cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Pneumococcal infections

Highest Development Phases

  • Suspended Pneumococcal infections

Most Recent Events

  • 28 Oct 2016 Genocea Biosciences plans a phase II trial in Pneumococcal infections (Prevention, In infants, In toddlers)
  • 09 Jun 2016 GEN 004 is available for licensing as of 09 Jun 2016
  • 05 May 2016 Genocea Biosciences completes a phase II trial in Pneumococcal infections (Prevention in healthy volunteers) in United Kingdom (NCT02116998)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top